XNAS · Healthcare · Biotechnology
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | -0.68 | -0.42 | +38.24% | $20.0M | ✅ Beat | +1.24% | -4.96% | -9.59% |
| 2026-03-10 | Q4 2025 | -0.66 | -0.72 | -9.09% | $0 | ❌ Miss | +2.49% | -6.41% | +15.49% |
| 2025-11-06 |
| Q3 2025 |
| -0.75 |
| -0.71 |
| +5.33% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-03-11 | Q4 2024 | -0.61 | -0.57 | +6.56% | $0 | ✅ Beat | +11.72% | +10.83% | -3.68% |
| 2024-11-07 | Q3 2024 | -0.57 | -0.50 | +12.28% | $0 | ✅ Beat | -0.78% | -18.29% | -23.68% |
Showing last 5 quarters.